Ark Therapeutics Limited

Imperial Cancer Research Technology, Ltd.

Arktherapeutics Group, Plc

Ian Zachary

David Lawrence Selwood

Haiyan Jia

Basil Hartzoulakis

Chris Chapman

Ashley Jarvis

Rosemary Lynch

Michelle Tickner

Jamie Nally

Mark Stewart

Lili Cheng

Katie Ellard

Dana Davis

Enrique Rozengurt

Penella Woll

Marianne Lohr

The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.

Arginine derivatives with NP-1 antagonistic activity

The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. 

Arginine derivatives with NP-I antagonistic activity

A peptide having part or all of the amino acid sequence QKRKRKKSRYKSWSVP (which is part of VEGF) has the ability to inhibit angiogenesis.

VEGF peptides and their use for inhibiting angiogenesis

A 75-85 Kd glycopolypeptide, capable of acting as a receptor for polypeptide of the bombesin type, is isolated from the surface of Swiss 3T3 cells. Certain antagonists and antibodies to the glycopolypeptide are described, the antagonists being of quite different structure to bombesin e.g. .differential.D-Pro.sup.2 [-spantide, .differential.D-Phe.sup.5 [-spantide and position 5 variants thereof. The antagonists and antibodies are of interest medically in that they are able to influence cell proliferation that occurs under the influence of the bombesin-like polypeptides.

Growth factor receptors

Growing community of inventors

London, United Kingdom

Ian Zachary